University of California/Tufts CTSI
Aug 8, 2025, 17:15
Patent Foramen Ovale and Stroke: David Kent and Andy Wang Break It Down
Vasculearn Network shared an insightful post on LinkedIn:
”ICYMI: PFO and Stroke – Who Benefits from Closure?
About 1 in 4 adults has a PFO, but not everyone needs it closed. A new July 2025 JAMA review reframes PFO closure as targeted, not routine, therapy for select stroke patients.
Key tools guiding treatment:
- RoPE score: Predicts if stroke is PFO-related
- PASCAL system: Adds anatomy to assess stroke causality
Best candidates?
- Age ≤60
- Cryptogenic stroke
- High PASCAL score
- No vascular risk factors
In these patients, closure cuts stroke recurrence risk by up to 90% at 2 years.
Everyone else? Medical therapy still leads with individualized decisions on antiplatelet vs. anticoagulant”
Find the full update on the community.
Read the full article here.
Article: Patent Foramen Ovale and Stroke. A Review
Authors: David M. Kent, Andy Y. Wang
Stay informed on all the scientific advances in hematology with Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine